SCHEMBL2299409

SCHEMBL2299409

CCOC(=O)C(CC#N)N1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
MAPK1 P28482 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
SLC6A3 Q01959 11/20 0.41
SLC6A2 P23975 9/20 0.41
SLC6A4 P31645 6/20 0.40
ALDH1A1 P00352 4/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12386296 0.85 MEN1 (0.41) MAPTMAPK1NPSR1L3MBTL1SLC6A3
SCHEMBL23376910 0.77 MAPT (0.64) MAPTMAPK1NPSR1L3MBTL1SLC6A3
SCHEMBL28046877 0.77 L3MBTL1 (0.46) MAPTMAPK1NPSR1L3MBTL1SLC6A3
SCHEMBL28794446 0.77 MAPT (0.64) MAPTMAPK1NPSR1L3MBTL1SLC6A3
SCHEMBL9341315 0.75 MAPT (0.55) MAPTMAPK1NPSR1L3MBTL1SLC6A3
SCHEMBL10589007 0.75 NPSR1 (0.50) MAPTMAPK1NPSR1L3MBTL1SLC6A3
SCHEMBL6737298 0.73 ALDH1A1 (0.43) MAPTMAPK1NPSR1L3MBTL1ALDH1A1
SCHEMBL20589054 0.73 ALDH1A1 (0.43) MAPTMAPK1NPSR1L3MBTL1ALDH1A1
SCHEMBL15415598 0.72 ALDH1A1 (0.42) MAPTMAPK1NPSR1L3MBTL1ALDH1A1
SCHEMBL2961890 0.72 ALDH1A1 (0.42) MAPTMAPK1NPSR1L3MBTL1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994176-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-08-09 US disclosed
EP-2021337-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-01-13 EP disclosed
EP-2021337-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-01-13 EP disclosed
US-20090099182-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
EP-2021337-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-02-11 EP disclosed
WO-2007127726-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed
WO-2007127726-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099182-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 MAPT 4430/4885MAPK1 319/4885NPSR1 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.